Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2014 Apr 22;9(4):e95856. doi: 10.1371/journal.pone.0095856

The Association of 5-HT2A, 5-HTT, and LEPR Polymorphisms with Obstructive Sleep Apnea Syndrome: A Systematic Review and Meta-Analysis

Baodong Qin 1,#, Zhen Sun 1,#, Yan Liang 1,#, Zaixing Yang 1,*, Renqian Zhong 1,*
Editor: Thomas Penzel2
PMCID: PMC3995918  PMID: 24755731

Abstract

Objective

A consensus has not been reached regarding the association of several different gene polymorphisms and susceptibility to obstructive sleep apnea syndrome (OSAS). We performed a meta-analysis to better evaluate the associations between 5-HT2A, 5-HTT, and LEPR polymorphisms, and OSAS.

Method

5-HT2A, 5-HTT, and LEPR polymorphisms and OSAS were identified in PubMed and EMBASE. The pooled odd rates (ORs) with 95%CIs were estimated using a fixed-effect or random-effect models. The associations between these polymorphisms and OSAS risk were assessed using dominant, recessive and additive models.

Results

Twelve publications were included in this study. The -1438 “A” allele of 5-HT2A was identified as a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49–3.66). Individuals carrying the -1438 “G” allele had a nearly 70% reduced risk of OSAS when compared with AA homozygotes (OR: 0.30, 95%CI 0.23–0.40). There was no significant association between 5-HT2A 102C/T and OSAS risk, using any model. The “S” allele of 5-HTTLPR conferred protection against OSAS (OR: 0.80, 95%CI 0.67–0.95), while the “10” allele of 5-HTTVNTR contributed to the risk of OSAS (OR: 2.08, 95%CI: 1.58–2.73). The “GG” genotype of LEPR was associated with a reduced risk of OSAS (OR: 0.39, 95%CI 0.17–0.88).

Conclusion

The meta-analysis demonstrated that 5-HTR-1438 “A” and 5-HTTVNTR “10” alleles were significantly associated with OSAS. The “S” allele of 5-HTTLPR and the “GG” genotype of LEPR conferred protection against OSAS. Further studies, such as Genome-Wide Association study (GWAS), should be conducted in a large cohort of OSAS patients to confirm our findings.

Introduction

Obstructive sleep apnea syndrome (OSAS) is a respiratory disorder characterized by upper airway obstruction during sleep, breathing pauses with oxygen desaturation, and arousal from sleep. OSAS is the third most prevalent respiratory disease after asthma and chronic obstructive pulmonary disease [1]. It has been estimated that about 2–4% of middle-aged people are affected by OSAS. OSAS is recognized as a chronic, complex disease related to metabolic syndrome, cardiovascular disease, neurocognitive and mood disorders [2]. With the rise in overweight and obesity, the prevalence of OSAS should increase, representing a serious public-health problem with substantial social and economic costs [3].

Although the pathogenetic mechanism of OSAS remains unclear, many factors have been incriminated. A combination of genetic makeup and environmental factors could contribute to the development of OSAS. The high concordance of first-degree relatives with OSAS, family clustering, and ethnic differences show that genetic factors may play an important role in the pathogenesis of OSAS [4]. It has been reported that genetic factors could account for about 40% of the variance in the apnea-hypopnea index (AHI) of OSAS patients [5]. It is currently thought that multiple gene interactions in a suitable environment may lead to OSAS [6].

Evaluation of the genetic contribution to the occurrence of OSAS is of interest [7]. Several polymorphisms have been suggested to play a role and a number of family and SNP studies have been performed. Serotonin (5-hydroxytryptamine; 5-HT) regulates a variety of physiological functions through 5-HT receptors (5-HT2A, 5-HT2B, 5-HT2C). These play a critical role in the patency of the upper airway and the prevention of glossocoma. A functional gene polymorphism of 5-HT2A has been identified to alter gene transcription, thus influencing the expression level of the receptor [8]. Polymorphisms in the 5-HT2A gene, characterized by reduction of receptor number and serotonin concentration in postsynaptic neurons, were associated with the development of OSAS [9], [10]. 5-HT reuptake is mediated by the serotonin transporter (5-HTT) [11], [12]. Polymorphisms of this gene could lead to alterations in 5-HT concentrations. Two such polymorphisms (variable number tandem repeat (VNTR) and 5-HTTLPR) have been described [13], [14]. Uptake of serotonin in cells with the “L/L” 5-HTTLPR genotype was more than that in cells carrying the “S/L” or “S/S” genotypes. The S allele was responsible for low uptake activity. Leptin is an adipocyte-derived hormone which plays an important role in metabolic control. The potential associations of leptin and LEPR gene polymorphisms with OSAS have been assessed in different populations [15]. Although the relationship between 5-HT2A, 5-HTT, LEPR and OSAS has been evaluated, the results were not consistent. To date, no large-scale Genome-Wide Association study (GWAS) has been performed. We performed a meta-analysis to better evaluate the association between reported polymorphisms and OSAS risk.

Methods

Search Strategy

We searched PubMed and EMBASE in all languages for relevant studies. The final date for inclusion was March 10, 2013. Comprehensive search themes included Medical Subject Headings (MeSH) terms and keywords: “sleep apnea”; “obstructive sleep apnea Syndrome”; “sleep apnea/hypopnea syndrome” and “serotonin 2A receptor(5-HT2A)”; “serotonin transporter protein(5-HTT)”; “leptin receptor (LEPR)”; “polymorphism”; ”variant”; and “genotype”.

Study selection

Inclusion criteria for this study were: (1) OSAS patients must be clearly diagnosed; (2) the study must be a case-control study; (3) the study should report enough genotyping information to extract and estimate odds ratios (ORs) with a 95% confidence interval (CI). Studies were excluded if: (1) the diagnosis was unclear; (2) the study did not contain sufficient data for extraction; (3) the study design was based on case, family or sibling pairs; or (4) no control group was included in the study. When overlapping reports occurred, the study with largest number of patients was selected.

Data extraction

All included studies were retrieved and the required information was extracted separately, in duplicate, by two authors (BDQ and SZ). Any discrepancies were resolved by discussion and agreement. The characteristics collected from each study were: author, year of publication, country, age, AHI, sample size, diagnosis criteria, genotype, allele frequency, and specific technique of analysis. If the allele frequency was not given, it was calculated from the corresponding genotype distributions. The OR with its 95%CI was extracted or calculated for each study.

Assessment of study quality

There is no standard quality criteria for single nucleotide polymorphism (SNP) studies, so we employed a modified Newcastle-Ottawa scale (NOS) score system to assess the quality of these non-randomized studies [16]. A total of eight items are included in the NOS. These are divided into three categories describing selection, comparability and exposure. A maximum of two stars was given for each of these items. A study awarded 0–3 stars was classified as a low quality study, while 4–6 stars and 7–9 stars were moderate and high quality studies, respectively [17].

Statistical analysis

We performed a systematic review and meta-analysis following a predetermined protocol in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines [18]. A meta-analysis was performed of polymorphisms of the 5-HT2A, 5-HTT, and LEPR genes, to examine their association with OSAS using additive, recessive and dominant models. The pooled ORs with 95%CIs were calculated in random-effects or fixed-effects models to measure the strength of the associations between these polymorphisms and OSAS risk. Heterogeneity of effects across studies was evaluated using the means of χ2-based Q test and I2 test. P<0.10 was considered to be representative of significant heterogeneity with the Q test. The I2 statistic represented quantification of heterogeneity ranging from 0% to 100%. Hundred percent represented a high degree of heterogeneity and 50%-<100% represented substantial heterogeneity [19]. If there was significant heterogeneity (P<0.10 for Q test; I2>50% for I2 test), a random-effects model was used to pool the data. Otherwise, a fixed-effects model was used. A funnel plot was employed to visually assess potential publication bias in meta-analyses including more than five studies. The Egger's regression asymmetry test and Begg's rank correlation test were used to statistically examine publication bias. A sensitivity analysis was performed to assess the impact of each individual study upon the overall ORs, using the one-study removal approach [20]. Hardy-Weinberg Equilibrium was assessed using χ2 tests for the polymorphism investigated in each study. All analyses were conducted using STATA 11.0 (StataCorp, College Station TX, USA). P<0.05 was considered statistically significant.

Result

Studies selection

Two hundred fifty-six non-overlapping articles were identified in the initial published work search. Two hundred eighteen articles were excluded based on screening of abstracts or titles. Thirty-eight full-text articles were retrieved and assessed for eligibility. Twenty-six of these articles were excluded ( Figure 1 ), leaving twelve eligible studies in this present study.

Figure 1. The flowchart showing articles identification, inclusion and exclusion.

Figure 1

Characteristics of included studies

Nine of the twelve studies included were in English and three in were Chinese. One thousand twenty OSAS patients and one thousand eighty-three control subjects were reported [9], [10], [13][15], [21][27]. Six of the twelve studies were conducted to clarify the association between 5-HT2A polymorphisms and OSAS. These studies included 728 OSAS patients and 566 controls subjects. Four studies evaluated 5-HTT polymorphisms and included 521 OSAS patients and 755 control subjects. Three studies evaluated the LEPR polymorphism and included 292 OSAS patients and 167 control subjects. ORs with 95% CIs were extracted from each study. A database was established for the information or characteristics extracted from these studies ( Table 1 and Table 2 ). The 12 reports included patients of American (n = 1), Asian (n = 8), and European (n = 3) ethnicity. The number of patients in each report ranged from 100 to 592. The diagnosis of OSAS was based on symptoms and polysomnography (PSG). Hardy-Weinberg equilibrium testing showed deviation from HWE in some of the studies (Table S1).

Table 1. Characteristic of the included studies about the association between 5-HT2A polymorphism and OSAS risk.

Author Year Country Age(Case/Control) AHI(Case/Control) Case/Control Diagnosis Genotype Method Genotype Frequency
Genotype OSAS Control
102C/T Yin, et al 2011 China 41.4±9.2 42.3±22.1 210/105 PSG AHI ≥5 events/h PCR TT 52 30
40.6±10.4 2.3±1.6 CT 107 51
CC 51 24
Sakai, et al 2005 Japan 48.3±10.1 46.1±25.8 177/100 PSG AHI ≥5 events/h PCR TT 47 25
38. ±11.1 NS CT 90 46
CC 40 29
Bayazit, et al 2006 Turkey NS NS 55/102 PSG PCR TT 17 28
NS NS Muller Maneuver CT 21 54
Laryngoscopy CC 17 20
De Carvalho, et al 2013 brazil 50.6±11.1 32.6±25.7 100/100 PSG AHI ≥5 events/h PCR TT 23 20
44.6±12.0 1.9±1.5 CT 66 69
CC 11 11
Zhu, et al 2007 China 44.2±2.0 NS 65/54 PSG PCR TT 18 15
43.0±2.1 NS CT 30 28
CC 17 11
Chen, et al 2013 China 43.8±3.0 42.6±14.8 121/105 PSG AHI ≥5 events/h PCR TT 34 29
43.0±2.7 3.7±1.3 AHI ≥15 events/h CT 56 54
CC 31 22
-1438 G/A Yin, et al 2011 China 41.4±9.2 42.3±22.1 210/105 PSG AHI ≥5 events/h PCR AA 85 17
40.6±10.4 2.3±1.6 AG 82 67
GG 43 21
Bayazit, et al 2006 Turkey NS NS 55/102 PSG PCR AA 24 25
NS NS Muller Maneuver AG 29 50
Laryngoscopy GG 12 27
Piatto, et al 2011 brazil 50.6±11.1 32.6±25.7 100/100 PSG AHI ≥5 events/h PCR AA 35 19
44.6±12.0 1.9±1.5 AG 61 71
GG 4 10
Zhu, et al 2007 China 44.2±2.0 NS 65/54 PSG PCR AA 41 15
43.0±2.1 NS AG 15 14
GG 9 25
Chen, et al 2013 China 43.8±3.0 42.6±14.8 121/105 PSG AHI ≥5 events/h PCR AA 74 28
43.0±2.7 3.72±1.28 AG 30 28
GG 17 49

NS: None Stated.

⊢: Indicated age of OSAS patients group in these studies.

: Indicated age of Control group in these studies.

Table 2. Characteristic of the included studies about the associations between 5-HTT, LEPR polymorphisms and OSAS risk.

Author Year Country Age(Case/Control) AHI(Case/Control) Case/Control Diagnosis Genotype Method Genotype Frequency
Genotype OSAS Control
5-HTT Chen, et al 2013 China 43.8±3.0 42.6±14.8 121/105 PSG AHI ≥5 events/h PCR) SS 59 55
LPR 43.0±2.7 3.7±1.3 AHI ≥15 events/h SL 35 34
LL 27 16
Ylmaz, et al 2005 Turkey NA NS 42/162 PSG PCR SS 6 60
NA NS SL 16 71
LL 4 35
Yue, et al 2008 China 45.2±11.8 53.9±16.4 254/338 PSG AHI ≥5 events/h PCR SS 114 173
43.2±12.7 NS SL 106 131
LL 34 34
Yue, et al 2005 China 42.3±10.1 NS 104/150 PSG AHI ≥10 events/h PCR SS 51 78
NA NS SL 33 54
LL 20 18
5-HTT Chen, et al 2013 China 43.8±3.0 42.6±14.8 121/105 PSG AHI ≥5 events/h PCR 10/10 8 1
VNTR 43.0±2.7 3.7±1.3 AHI ≥15 events/h 10/12 24 10
12/12 89 94
Ylmaz, et al 2005 Turkey NA NS 42/162 PSG PCR 10/10 3 14
NA NS 10/12 13 61
12/12 9 93
Yue, et al 2008 China 45.2±11.8 53.9±16.4 254/338 PSG AHI ≥5 events/h PCR 10/10 6 3
43.2±12.7 NS 10/12 46 41
12/12 202 294
Yue, et al 2005 China 42.3±10.1 NS 104/150 PSG AHI ≥10 events/h PCR 10/10 3 1
NA NS 10/12 20 14
12/12 81 135
LEPR Popko, et al 2007 Poland 21–77 >5 102/77 PSG AHI ≥5 events/h PCR assay Gln/Gln 18 26
18–65 <5 Gln/Arg 61 40
Arg/Arg 23 11
Hanaoka, 2008 Japan 50.3±2.0 49.1±3.9 130/50 PSG AHI ≥10 events/h PCR Gln/Gln 63 21
et al 50.0±4.4 2.1±0.5 Gln/Arg 57 28
Arg/Arg 5 1
Huang, 2003 China 43.4±0.8 NS 60/40 PSG PCR-RFLP Gln/Gln 79 64
et al 43,9±1.2 NS Gln/Arg 22 23
Arg/Arg 2 1

NS: None Stated.

⊢: Indicated age of OSAS patients group in these studies.

: Indicated age of Control group in these studies.

5-HT2A 102 C/T and OSAS

Six studies evaluated the association between 5-HT2A 102C/T and OSAS. The pooled data revealed no significant association between 5-HT2A 102C/T polymorphism and OSAS risk, using any model ( Table 3 ). The frequency of the minor “C” allele was not significantly different in OSAS patients and controls (OR: 0.97, 95%CI 0.83–1.14), suggesting that the polymorphism was not linked to OSAS development. There was no significant heterogeneity in this meta-analysis. Subgroup meta-analysis stratified by ethnicity found no significant association with Caucasian or Asian populations.

Table 3. Meta-analysis of associations between 5-HT2A, 5-HTT, LEPR polymorphisms and OSAS in the additive, dominant and recessive Models.

SNP Comparison OR with 95%CI Heterogeneity Publication Bias
χ2 Q test I2 Tau2 Begg's test Egger's test
5-HT2A 102 C/T T vs C 0.97(0.83–1.14) 2.02 0.846 0.00% 0 0.707 0.449
TT vs CT 1.07(0.81–1.40) 1.98 0.852 0.00% 0 0.133 0.087
TT vs CC 0.93(0.67–1.29) 2.07 0.839 0.00% 0 1.000 0.699
CC vs CT 1.13(0.84–1.50) 5.63 0.344 11.20% 0.017 0.452 0.213
TT+CT vs CC 0.90(0.69–1.19) 4.67 0.458 0.00% 0 1.000 0.316
CC+CT vs TT 0.98(0.76–1.26) 1.06 0.957 0.00% 0 0.707 0.263
5-HT2A-1438 G/A A vs G 2.33(1.49–3.66) 22.9 0 82.60% 0.217 0.462 0.458
AA vs GG 4.22(2.38–7.49) 8.49 0.075 52.90% 0.222 1.000 0.989
GG vs AG 0.66(0.31–1.40) 15.2 0.004 73.60% 0.524 0.806 0.296
AA vs AG 2.78(2.03–3.81) 2.33 0.675 0.00% 0 0.806 0.543
AA+AG vs GG 2.44(1.11–5.38) 20.8 0 80.70% 0.637 0.806 0.631
GG+AG vs AA 0.30(0.23–0.40) 3.53 0.473 0.00% 0 0.806 0.747
5-HTTLPR S vs L 0.80(0.67–0.95) 0.07 0.995 0.00% 0 1.000 0.435
SS vs LL 0.65(0.46–0.93) 0.27 0.966 0.00% 0 1.000 0.396
SS vs SL 0.86(0.67–1.11) 2.76 0.430 0.00% 0 0.713 0.713
SL vs LL 0.77 (0.54–1.11) 3.60 0.308 16.70% 0.031 0.734 0.547
SS+SL vs LL 0.72(0.51–1.01) 0.22 0.977 0.00% 0 0.734 0.285
LL+SL vs SS 1.25(0.99–1.59) 0.98 0.805 0.00% 0 0.734 0.557
5-HTTVNTR 10 vs 12 2.08(1.58–2.73) 3.31 0.346 9.40% 0.089 0.278
10/10 vs 12/12 3.75(1.67–8.45) 1.29 0.731 0.00% 0 0.734 0.135
10/10 vs 10/12 1.67(0.74–3.77) 0.94 0.816 0.00% 0 0.308 0.236
10/12 vs 12/12 1.97(1.42–2.73) 1.35 0.718 0.00% 0 0.734 0.090
10/10+10/12 vs 12/12 2.14(1.57–2.91) 2.10 0.551 0.00% 0 0.734 0.187
10/10 vs 12/12+10/12 3.00(1.39–6.46) 1.89 0.596 0.00% 0 0.308 0.141
LEPR G vs A 0.78(0.58–1.05) 3.73 0.155 46.40% 0.009 1.000 0.791
GG vs AA 0.39(0.17–0.88) 0.40 0.818 0.00% 0 1.000 0.042
GG vs AG 0.80(0.40–1.59) 5.62 0.060 64.40% 0.241 1.000 0.517
AA vs AG 1.46(0.71–3.04) 0.27 0.875 0.00% 0 1.000 0.703
AA+AG vs GG 1.32(0.65–2.67) 6.11 0.047 67.30% 0.260 1.000 0.652
GG+AG vs AA 0.57(0.28–1.15) 0.03 0.984 0.00% 0 1.000 0.958

5-HT2A-1438 G/A and OSAS

Five studies evaluated the association between -1438 G/A polymorphism and OSAS. Dominant and recessive models were examined. Individuals carrying the “G” allele (AG+GG) had a nearly 70% reduced risk for the development of OSAS, when compared with AA homozygotes (OR: 0.30, 95%CI 0.23–0.40). Individuals with the “A” allele were more susceptible to OSAS than GG homozygotes (OR: 2.44, 95%CI 1.11–5.38). Using the additive model, a significant association was found (OR: 2.78, 95%CI 2.03–3.81 for AA vs. AG; OR: 4.22, 95%CI 2.38–7.50 for AA vs. GG). AA carriers had an increased risk of OSAS compared with individuals having an AG or GG genotype. Significant heterogeneity was observed in the recessive and additive models ( Table 3 ). The -1438 “A” allele was a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49–3.66). There was significant heterogeneity across the studies with respect to the association between the “A” allele and OSAS risk (p<0.05, I2 = 82.60%) ( Figure 2 ). The association was much stronger in Asian patients than in Caucasian patients. Assessment of bias indicated that heterogeneity was mainly found across the studies based on Asian populations rather than Caucasian populations. This supports the finding that ethnicity may contribute to the high degree of heterogeneity. Due to the small number of included studies, subgroup meta-analyses and assessment of bias by other factors could not be conducted.

Figure 2. Forest plot of the association between 5-HT2A-1438(A vs. G), 5-HTT-LPR(S vs. L), 5-HTT-VNTR (10 vs. 12), LEPR-Gln223Arg (GG vs. AA) and OSAS risk in the overall population (a: Meta-analysis with a random-effects model; b, c, d: Meta-analysis with a fixed-effects model).

Figure 2

5-HTT-LPR and OSAS

Four studies evaluated the association of 5-HTT-LPR polymorphisms with OSAS ( Table 2 ). The meta-analysis revealed that the “S” allele conferred protection against OSAS (OR: 0.80, 95%CI 0.67–0.95). Individuals with the “S” allele had a 20% lower risk of OSAS than individuals with the “L” allele ( Figure 2 ). The additive model demonstrated a greater association of the “SS” genotype with OSAS than that of the “LL” genotype (OR: 0.65, 95%CI 0.46–0.93). There was no significant heterogeneity across the studies. The subgroup meta-analysis of ethnicity could not be performed due to the small sample size.

5-HTT-VNTR and OSAS

Four studies evaluated the relationship of 5-HTT-VNTR polymorphisms with OSAS. The “10” allele was significantly associated with OSAS (OR: 2.08, 95%CI: 1.58–2.73) ( Figure 2 ). The additive, recessive, and dominant models all showed a significant increased risk of OSAS among individuals with the “10” allele. The positive association was strongest when individuals with the “10/10” genotype” were compared with those carrying the “10/12” genotype (OR: 3.75, 95%CI: 1.7–8.45). No significant heterogeneity was found across these 4 studies.

LEPR- Gln223Arg and OSAS

Three studies evaluated the relationship between LEPR- Gln223Arg and OSAS. The “GG” genotype” was associated with a low risk for OSAS, when compared with the “AA” homozygote (OR: 0.39, 95%CI 0.17–0.88) ( Figure 2 ). A significant association was not found using recessive and dominant models. The risk of having OSAS in individuals with the “G” allele was 0.78. This was not significantly different from the “AA” allele (95%CI 0.58–1.05).

Sensitivity analysis

Sensitivity analyses were performed when more than 3 studies were involved. The stability and reliability of pooled ORs were examined using the leave-one-out method. This method repeated the meta-analysis after sequential exclusion of each study. The estimated ORs were not significantly influenced by any individual study.

Publication bias

The funnel plots for associations between 5-HT2A 102C/T, 5-HT2A-1438G/A, and OSAS did not visually demonstrate significant publication bias (Data not shown). Both Begg's test and Egger's tests demonstrated no publication bias ( Table 3 ).

Study quality

The NOS scoring system was used to evaluate study quality. Five studies scored 8 stars, 5 studies scored 7 stars, 1 study scored 6 stars, and 1 study scored 5 stars (Table S2).

Discussion

The contribution of genetic factors to the development of OSAS is supported by the increased risk of OSAS in first-degree relatives and siblings of OSAS patients. The association between genetic polymorphisms and susceptibility to OSAS remains poorly defined due conflicting data. We conducted a systematic review of published studies investigating the role of 5-HT2A, 5-HTT, and LEPR polymorphisms in OSAS and performed a meta-analysis of these studies. 5-HT2A-1438G/A, 5-HTT-LPR, 5-HTT-VNTR, and LEPR-Gln223Arg were associated with the development of OSAS. 5-HT2A-1438 “A” and 5-HTT-VNTR “10” alleles were genetic risk factors for OSAS, while the 5-HTT-LPR “S” allele was a low risk factor for OSAS. Individuals with the “GG” LEPR-Gln223Arg genotype had a lower risk of OSAS compared to those with the “AA” genotype.

Twelve studies published between 2003 and 2013 were included in this study. Ten studies were of high quality, 2 of medium quality and no study was of low quality. These findings support the results of this study as a meaningful analysis of the available data.

The association of SNPs in the 5-HT2A, 5-HTT, and LEPR genes with OSAS has been reported with conflicting results. There is no previous meta-analysis of these reports. We found no association between 5-HT2A and 102T/C, and OSAS. The -1438G/A polymorphism of the 5-HT2A gene was associated with the development of OSAS. The -1438 “A” allele was associated with OSAS. This positive association was observed in all reports we evaluated. The “AA” genotype of 5-HT2A-1438G/A was over-represented in OSAS patients. Individuals carrying the “AA” genotype had a greater risk of OSAS than those with the “GG” genotype (OR  = 4.22). Bayazit et al. did not identify this positive association between “AA” genotype and OSAS risk. Yin found that the “AA' genotype was over-expressed in patients with LSaO2 ≤75%. Both Chen et al. and Bayazit et al. found the frequency of “AA” genotype to be significantly higher in male OSAS patients. There were not enough patients in the studies we reviewed to perform these subgroup analyses.

The LPR VNTR polymorphism in the 5-HTT gene correlated with the occurrence of OSAS in some, but not all, studies. A meta-analysis was performed to better evaluate the association between LPR VNTR polymorphisms and OSAS. The “S” allele of 5-HTT-LPR and “SS” genotype was associated with a lower frequency of OSAS. The frequency of the “10” allele in the 5-HTT-VNTR was significantly higher in OSAS patients, suggesting that it was a risk factor for OSAS. These findings were consistent with those of Chen et al. and Yue et al., but not Yilmaz et al. Another observation made here was that the frequency of the “GG” genotype in exon 6 of the LEPR gene was significantly lower in OSAS patients than controls, suggesting this genotype was low risk factor.

Polymorphisms related to the development of OSAS mainly lie in the serotoninergic system, an important component of sleep and airway function during sleep. In vitro studies have shown that polymorphisms of the 5-HTR 2A/2C genes influence receptor expression [28]. These findings give better insight into the development of OSAS and physiopathology of the disorder [29].

The GWAS has given better insight into the genetic nature of human disease, and identified several disease specific genes. The small sample size of previous studies and of this meta-analysis show the need for GWASs of large numbers of OSAS patients in order to better detect genetic associations. The GWAS approach could detect new disease genes, give clues to the pathogenesis of OSAS, and provide indicators for diagnosis, treatment, and prevention of the disease.

There were several limitations to this study. The number of included studies was relatively small, restricting the power of the study. Previous studies have shown associations between gender, SaO2, severity of disease and gene polymorphisms. The small number of patients identified in our literature review did not allow subgroup meta-analysis. The publications included in this study designed to evaluate the roles of different gene polymorphisms in OSAS. These different study designs could be a potential source of bias. Ongoing, unpublished and missing studies from the literature review could have contributed to publication bias, although the funnel plots, Egger' test and Begg's test did not identify any bias. Finally, a combination of susceptibility genes and environmental factors could contribute to the development of OSAS. Our study could not evaluate gene-gene and gene–environment interactions due to the small number of patients identified. These findings need to be studied in a large cohort of OSAS patients in the future.

In conclusion, our study demonstrated that 5-HT2R, 5-HTT, and LEPR polymorphisms were significantly associated with the development of OSAS. 5-HT2A-1438 “A” and 5-HTT-VNTR “10” were independent risk factors for OSAS. The “S” allele of 5-HTT-LPR and the “GG” genotype of Gln223Arg in the LEPR gene conferred protection against OSAS. The small sample size may have affected the accuracy of our findings. GWAS is needed to better detect candidate disease genes and to expand our understanding of the genetic background of OSAS. Future research should also focus on the clinical relevance of these findings.

Supporting Information

Table S1

The HWE test for ACE(I/D), TNF-α-308 A/G, 5-HT2A-102C/T, 5-HT2A-1438G/A, 5-HTT LPR, 5-HTT VNTR, LEPR genotype distribution in included studies.

(DOC)

Table S2

Methodological quality of included studies according to the NEWCASTLE-OTTAWA Quality Assessment Scale.

(DOCX)

Checklist S1

PRISMA Checklist.

(DOC)

Acknowledgments

Contributions

Conceived and designed the experiments: ZY RQZ. Performed the experiments: BDQ ZS. Analyzed the data: ZXY YL. Contributed reagents/materials/analysis tools: BDQ ZS. Wrote the paper: BDQ RQZ. No.

Funding Statement

This study was supported by two grants from the China National Natural Science Foundation Council (81001333 and 81072479). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, et al. (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328: 1230–1235. [DOI] [PubMed] [Google Scholar]
  • 2. Bradley TD, Floras JS (2009) Obstructive sleep apnoea and its cardiovascular consequences. Lancet 373: 82–93. [DOI] [PubMed] [Google Scholar]
  • 3. Mannarino MR, Di Filippo F, Pirro M (2012) Obstructive sleep apnea syndrome. Eur J Intern Med 23: 586–593. [DOI] [PubMed] [Google Scholar]
  • 4. Schwab RJ, Pasirstein M, Kaplan L, Pierson R, Mackley A, et al. (2006) Family aggregation of upper airway soft tissue structures in normal subjects and patients with sleep apnea. Am J Respir Crit Care Med 173: 453–463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Redline S, Tishler PV, Tosteson TD, Williamson J, Kump K, et al. (1995) The familial aggregation of obstructive sleep apnea. Am J Respir Crit Care Med 151: 682–687. [DOI] [PubMed] [Google Scholar]
  • 6. Casale M, Pappacena M, Rinaldi V, Bressi F, Baptista P, et al. (2009) Obstructive sleep apnea syndrome: from phenotype to genetic basis. Curr Genomics 10: 119–126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Kent BD, Ryan S, McNicholas WT (2010) The genetics of obstructive sleep apnoea. Curr Opin Pulm Med 16: 536–542. [DOI] [PubMed] [Google Scholar]
  • 8. Huang J, Liao N, Huang QP, Xie ZF (2012) Association between tumor necrosis factor-(alpha)-308G/A polymorphism and obstructive sleep apnea: A meta-analysis. Genetic Testing and Molecular Biomarkers 16: 246–251. [DOI] [PubMed] [Google Scholar]
  • 9. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25: 603–605. [DOI] [PubMed] [Google Scholar]
  • 10. Liang Y, Yang Z, Zhong R (2012) Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 56: 1409–1417. [DOI] [PubMed] [Google Scholar]
  • 11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012. [DOI] [PubMed] [Google Scholar]
  • 12. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558. [DOI] [PubMed] [Google Scholar]
  • 13. Biros E, Norman PE, Jones GT, van Rij AM, Yu G, et al. (2011) Meta-analysis of the association between single nucleotide polymorphisms in TGF-beta receptor genes and abdominal aortic aneurysm. Atherosclerosis 219: 218–223. [DOI] [PubMed] [Google Scholar]
  • 14. Yin G, Ye J, Han D, Zhang Y, Zeng W, et al. (2012) Association of the 5-HT2A receptor gene polymorphisms with obstructive sleep apnea hypopnea syndrome in Chinese Han population. Acta Oto-Laryngologica 132: 203–209. [DOI] [PubMed] [Google Scholar]
  • 15. Sakai K, Takada T, Nakayama H, Kubota Y, Nakamata M, et al. (2005) Serotonin-2A and 2C receptor gene polymorphisms in Japanese patients with obstructive sleep apnea. Internal Medicine 44: 928–933. [DOI] [PubMed] [Google Scholar]
  • 16. Bayazit YA, Yilmaz M, Ciftci T, Erdal E, Kokturk O, et al. (2006) Association of the -1438G/A polymorphism of the 5-HT2A receptor gene with obstructive sleep apnea syndrome. ORL 68: 123–128. [DOI] [PubMed] [Google Scholar]
  • 17. de Carvalho TB, Suman M, Molina FD, Piatto VB, Maniglia JV (2013) Relationship of obstructive sleep apnea syndrome with the 5-HT2A receptor gene in Brazilian patients. Sleep Breath 17: 57–62. [DOI] [PubMed] [Google Scholar]
  • 18. Zhu JY, Hu K, Ma ZS, Liu D (2007) The association between polymorphism of the serotonin 2A, 2C receptor genes and obstructive sleep apnea-hypopnea syndrome in Han population. Zhonghua jie he he hu xi za zhi  =  Zhonghua jiehe he huxi zazhi  =  Chinese journal of tuberculosis and respiratory diseases 30: 912–917. [PubMed] [Google Scholar]
  • 19.Chen H, Hu K, Zhu J, Xianyu Y, Cao X, et al.. (2013) Polymorphisms of the 5-hydroxytryptamine 2A/2C receptor genes and 5-hydroxytryptamine transporter gene in Chinese patients with OSAHS. Sleep Breath. [DOI] [PubMed]
  • 20. Ylmaz M, Bayazit YA, Ciftci TU, Erdal ME, Urhan M, et al. (2005) Association of serotonin transporter gene polymorphism with obstructive sleep apnea syndrome. Laryngoscope 115: 832–836. [DOI] [PubMed] [Google Scholar]
  • 21. Yue W, Liu H, Zhang J, Zhang X, Wang X, et al. (2008) Association study of serotonin transporter gene polymorphisms with obstructive sleep apnea syndrome in Chinese han population. Sleep 31: 1535–1541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Yue WH, Liu PZ, Hao W, Zhang XH, Wang XP, et al. (2005) Association study of sleep apnea syndrome and polymorphisms in the serotonin transporter gene. Chinese Journal of Medical Genetics 22: 533–536. [PubMed] [Google Scholar]
  • 23. Hanaoka M, Yu X, Urushihata K, Ota M, Fujimoto K, et al. (2008) Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. Chest 133: 79–85. [DOI] [PubMed] [Google Scholar]
  • 24. Huang R, Huang XZ, Li M, Xiao Y, Zhang J (2003) An investigation of the relationship between Lepr gene Gln223Arg polymorphism and obstructive sleep apnea hypopnea syndrome. Zhonghua jie he he hu xi za zhi  =  Zhonghua jiehe he huxi zazhi  =  Chinese journal of tuberculosis and respiratory diseases 26: 517–521. [PubMed] [Google Scholar]
  • 25. Popko K, Gorska E, Wasik M, Stoklosa A, Plywaczewski R, et al. (2007) Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. Journal of Physiology and Pharmacology 58: 551–561. [PubMed] [Google Scholar]
  • 26. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083–1152. [DOI] [PubMed] [Google Scholar]
  • 27. Riha RL, Gislasson T, Diefenbach K (2009) The phenotype and genotype of adult obstructive sleep apnoea/hypopnoea syndrome. Eur Respir J 33: 646–655. [DOI] [PubMed] [Google Scholar]
  • 28. Liu Y, Patel S, Nibbe R, Maxwell S, Chowdhury SA, et al. (2011) Systems biology analyses of gene expression and genome wide association study data in obstructive sleep apnea. Pac Symp Biocomput: 14–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Grilo A, Ruiz-Granados ES, Moreno-Rey C, Rivera JM, Ruiz A, et al. (2013) Genetic analysis of candidate SNPs for metabolic syndrome in obstructive sleep apnea (OSA). Gene. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table S1

The HWE test for ACE(I/D), TNF-α-308 A/G, 5-HT2A-102C/T, 5-HT2A-1438G/A, 5-HTT LPR, 5-HTT VNTR, LEPR genotype distribution in included studies.

(DOC)

Table S2

Methodological quality of included studies according to the NEWCASTLE-OTTAWA Quality Assessment Scale.

(DOCX)

Checklist S1

PRISMA Checklist.

(DOC)


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES